REBETOL®
(ribavirin)
CRIXIVAN®
(indinavir sulfate)
ISENTRESS®
(raltegravir)
DELSTRIGO
(doravirine,
lamivudine, and
tenofovir disoproxil
fumarate)
PIFELTRO
(doravirine)
GARDASIL®
[Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine]
GARDASIL®9
[human papillomavirus 9-valent vaccine, recombinant]
JANUVIA®
(sitagliptin phosphate)
JANUMET®
(sitagliptin/metformin HCl)
VARICELLA ZOSTER VIRUS-CONTAINING VACCINES


 

Please note that the Pregnancy Registry for JANUVIA and JANUMET is now CLOSED to new enrollment.

Enrollment was discontinued on July 6, 2022.

Merck wishes to convey its gratitude to the women and health care providers who reported exposure to JANUVIA or JANUMET during pregnancy.Their contributions allowed the ongoing surveillance of this product to monitor and describe its safety profile.

Healthcare providers are encouraged to report any exposures to JANUVIA or JANUMET during pregnancy. For questions related to exposure to JANUVIA or JANUMET during pregnancy or to report new cases of exposure to JANUVIA or JANUMET during pregnancy, please contact Merck's National Service Center at 1-877-888-4231.

 


 


CRIXIVAN  |  GARDASIL  |  GARDASIL 9  |  ISENTRESS  |  JANUVIA  |  JANUMET  |  PROQUAD  |  REBETOL  |  VARIVAX  |  ZOSTAVAX  | 
Home  |  Privacy  |  Terms of use  |  Accessiblity

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.